Lillian B Brown, PhD

Director, Clinical Development
Gilead Sciences, Inc.

Poster(s):

• (251) Preference for twice-yearly injections vs daily oral pills for HIV PrEP in cisgender men, transgender women, transgender men, and gender nonbinary people enrolled in PURPOSE 2
  Wednesday, October 29, 2025